Praxis Precision Medicines (PRAX) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Praxis Precision Medicines (NASDAQ: PRAX):

• 2/10/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $800.00 price target on the stock, up previously from $760.00.
• 2/4/2026 – Praxis Precision Medicines had its price target raised by analysts at Needham & Company LLC from $460.00 to $510.00. They now have a “buy” rating on the stock.
• 2/2/2026 – Praxis Precision Medicines is now covered by analysts at Wells Fargo & Company. They set an “equal weight” rating and a $282.00 price target on the stock.
• 1/30/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $1,245.00 price target on the stock, up previously from $340.00.
• 1/29/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at TD Cowen.
• 1/28/2026 – Praxis Precision Medicines had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $1,200.00 price target on the stock, up previously from $450.00.
• 1/12/2026 – Praxis Precision Medicines had its price target raised by analysts at Wedbush from $83.00 to $95.00. They now have an “underperform” rating on the stock.
• 1/5/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $460.00 price target on the stock.
• 1/2/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at TD Cowen.
• 12/30/2025 – Praxis Precision Medicines had its “conviction-buy” rating reaffirmed by analysts at Citigroup Inc..
• 12/30/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 12/29/2025 – Praxis Precision Medicines had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/29/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Guggenheim.
• 12/29/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $843.00 price target on the stock, up previously from $507.00.
• 12/22/2025 – Praxis Precision Medicines had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Praxis Precision Medicines had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Praxis Precision Medicines was given a new $750.00 price target on by analysts at UBS Group AG.
• 12/15/2025 – Praxis Precision Medicines had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $750.00 price target on the stock, up previously from $250.00.

Insider Activity

In related news, General Counsel Alex Nemiroff sold 25,130 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $193.09, for a total value of $4,852,351.70. Following the sale, the general counsel owned 20,832 shares of the company’s stock, valued at approximately $4,022,450.88. This trade represents a 54.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Lauren Mastrocola sold 13,600 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $192.08, for a total value of $2,612,288.00. Following the transaction, the insider owned 10,442 shares of the company’s stock, valued at $2,005,699.36. This represents a 56.57% decrease in their position. The SEC filing for this sale provides additional information. 2.70% of the stock is owned by corporate insiders.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.